480.20
-3.30%
Close of 10 Nov 2026, in SEK
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Swedish Orphan Biovitrum AB (publ)
Its shares trade on Nasdaq Stockholm under the ticker SOBI.ST. It has been listed since 15 September 2006. In the fiscal year to 31 December 2025, it reported revenue of SEK 28.24bn and net income of SEK 478.0m. At that date it held total assets of SEK 67.43bn and shareholders' equity of SEK 37.72bn.
Swedish Orphan Biovitrum AB engages in the research, development, manufacture, and sale of pharmaceutical. The company is headquartered in Solna, Stockholm. The company went IPO on 2006-09-15. The firm develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers pharmaceuticals within Inflammation area, and Genetics and metabolic therapeutic area; the Partner Products segment offers about 40 pharmaceuticals within hematology, oncology and emergency medicines, and the ReFacto Manufacturing segment. The firm has subsidiaries in Sweden, Denmark, Finland, Norway, United Kingdom and France, among others. On September 9, 2013, the Company acquired the full rights to develop and commercialize Kineret (anakinra) from Amgen, the biotechnology company based in the United States.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 15 Sept 2006
- Employees
- 1,377
- Website
- sobi.com ↗
Leadership
Pay as last reported
- Mr. David MeekIndependent Chairman of the BoardSEK 175,000
- Dr. Guido OelkersChief Executive OfficerSEK 55.5m
- Mr. Henrik StenqvistChief Financial Officer
- Ms. Christine WesstroemHead - Technical Operations
- Mr. Torbjoern HallbergGeneral Counsel and Head of Legal Affairs
- Ms. Lydia Adab-franchChief Medical Officer, Head of Research & Development
- Mr. Duane BarnesHead of North America
- Ms. Lena BjurnerHead of Human Resources
- Mr. Sofiane FahmyHead of Europe
- Mr. Mahmood LadhaHead of Strategic Transformation Operations
- Mr. Norbert OppitzHead of International
- Mr. Daniel RankinHead of Strategy and Corporate Development
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 89
- Environment
- 87
- Social
- 99
- Governance
- 80
- Direct emissions (scope 1)
- 1,097 t
- Energy emissions (scope 2)
- 852 t
- Value chain emissions (scope 3)
- 251,456 t
- Women in the workforce
- 59%
- Carbon reduction policy
- Yes
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Swedish Orphan Biovitrum AB (publ) holds several strengths that contribute to its success in the market. These strengths include:
Weaknesses
- Despite its strengths, Swedish Orphan Biovitrum AB (publ) also faces certain weaknesses that hinder its progress. These weaknesses include:
Opportunities
- Swedish Orphan Biovitrum AB (publ) can leverage the following opportunities to expand and enhance its market position:
Threats
- Swedish Orphan Biovitrum AB (publ) faces several threats that could hinder its growth and profitability:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.